ICYMI: EDSIVO for vEDS Earns Breakthrough Therapy Designation
stevepb / Pixabay

ICYMI: EDSIVO for vEDS Earns Breakthrough Therapy Designation

In the United States, the FDA grants Breakthrough Therapy designation to drugs intended to treat serious and life-threatening illnesses, and/or drugs which show significant improvement over available therapies. After receiving…

Continue Reading ICYMI: EDSIVO for vEDS Earns Breakthrough Therapy Designation

Editor’s Choice: Developments In Beta Thalassemia, Eosinophilic Esophagitis and Congenital Adrenal Hyperplasia

Happy Friday! This week, we have details on an investigational compound for beta thalassemia. Also, we break down the details of a new study that examines psychiatric illness rates among…

Continue Reading Editor’s Choice: Developments In Beta Thalassemia, Eosinophilic Esophagitis and Congenital Adrenal Hyperplasia